The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•31 March 2026•

1 min read

MAIA Biotechnology Reports Positive Survival Data in Phase 2 Lung Cancer Trial

Key Facts

1MAIA reported overall survival exceeding two years for eight patients in its ongoing Phase 2 THIO-101 clinical trial.

2The data was presented at the European Lung Cancer Congress (ELCC) 2026 in Copenhagen.

Version History

1 additional source confirmed this story

MAIA Biotechnology (NYSE American: MAIA) announced significant survival results from its ongoing Phase 2 THIO-101 clinical trial. The company reported that eight patients with non-small cell lung cancer (NSCLC) achieved overall survival exceeding two years during the study. These findings were presented at the European Lung Cancer Congress (ELCC) 2026 held in Copenhagen. The clinical study evaluates the efficacy of ateganosine sequenced with cemiplimab as a targeted immunotherapy treatment for cancer patients. MAIA aims to capture a share of the global immunotherapy market, which is currently valued at over $50 billion. While the patient cohort remains small, the long-term survival data provides a strong validation of the company's clinical pipeline and therapeutic approach.